ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Sawvic
|
10K |
4.9M |
4 |
16/02/22 |
16/02/22 |
ASX - By Stock
|
10K
|
4.9M
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Sawvic
|
10K |
4.9M |
3 |
16/02/22 |
16/02/22 |
ASX - By Stock
|
10K
|
4.9M
|
3
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Change in substantial holding
|
|
Sawvic
|
5 |
2.4K |
2 |
12/02/22 |
12/02/22 |
ASX - By Stock
|
5
|
2.4K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Sawvic
|
10K |
4.9M |
6 |
10/02/22 |
10/02/22 |
ASX - By Stock
|
10K
|
4.9M
|
6
|
|
ASX - By Stock
|
NEU |
Re:
ANAVEX MEETS ENDPOINTS PHASE2 RETT
|
|
Sawvic
|
166 |
77K |
1 |
09/02/22 |
09/02/22 |
ASX - By Stock
|
166
|
77K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
ANAVEX MEETS ENDPOINTS PHASE2 RETT
|
|
Sawvic
|
166 |
77K |
0 |
09/02/22 |
09/02/22 |
ASX - By Stock
|
166
|
77K
|
0
|
|
ASX - By Stock
|
CYC |
Re:
Ann: Cyclopharm USFDA Update
|
|
Sawvic
|
23 |
9.1K |
4 |
03/02/22 |
03/02/22 |
ASX - By Stock
|
23
|
9.1K
|
4
|
|
ASX - By Stock
|
CYC |
Re:
Ann: Half Year 2021 Financial Results
|
|
Sawvic
|
26 |
10K |
1 |
24/01/22 |
24/01/22 |
ASX - By Stock
|
26
|
10K
|
1
|
|
ASX - By Stock
|
MDR |
Re:
Social Media
|
|
Sawvic
|
184 |
76K |
1 |
21/01/22 |
21/01/22 |
ASX - By Stock
|
184
|
76K
|
1
|
|
ASX - By Stock
|
TRI |
Re:
Ann: Trading Halt
|
|
Sawvic
|
13 |
5.3K |
3 |
10/12/21 |
10/12/21 |
ASX - By Stock
|
13
|
5.3K
|
3
|
|
ASX - By Stock
|
TRI |
Re:
Ann: Trading Halt
|
|
Sawvic
|
13 |
5.3K |
5 |
10/12/21 |
10/12/21 |
ASX - By Stock
|
13
|
5.3K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Evans partners report on Neu
|
|
Sawvic
|
37 |
21K |
3 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
37
|
21K
|
3
|
|
ASX - By Stock
|
MDR |
Re:
Ann: Ceasing to be a substantial holder
|
|
Sawvic
|
4 |
961 |
0 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
4
|
961
|
0
|
|
ASX - By Stock
|
CYC |
Re:
Ann: Cyclopharm USFDA Update
|
|
Sawvic
|
16 |
7.5K |
5 |
29/06/21 |
29/06/21 |
ASX - By Stock
|
16
|
7.5K
|
5
|
|
ASX - By Stock
|
CYC |
Re:
Ann: Confirmation of Technegas USFDA Timetable
|
|
Sawvic
|
20 |
9.4K |
1 |
25/06/21 |
25/06/21 |
ASX - By Stock
|
20
|
9.4K
|
1
|
|
ASX - By Stock
|
CYC |
Re:
Ann: Confirmation of Technegas USFDA Timetable
|
|
Sawvic
|
20 |
9.4K |
5 |
20/06/21 |
20/06/21 |
ASX - By Stock
|
20
|
9.4K
|
5
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Trading Halt
|
|
Sawvic
|
157 |
69K |
9 |
17/06/21 |
17/06/21 |
ASX - By Stock
|
157
|
69K
|
9
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Reports Positive Final Data from INSIGHT-004 trial
|
|
Sawvic
|
12 |
6.0K |
0 |
04/06/21 |
04/06/21 |
ASX - By Stock
|
12
|
6.0K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Who is keeping the price down .
|
|
Sawvic
|
103 |
54K |
4 |
24/05/21 |
24/05/21 |
ASX - By Stock
|
103
|
54K
|
4
|
|
ASX - By Stock
|
MDR |
Re:
Ann: Quarterly Report and Appendix 4C
|
|
Sawvic
|
9 |
3.5K |
1 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
9
|
3.5K
|
1
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Becoming a substantial holder
|
|
Sawvic
|
14 |
5.5K |
4 |
20/04/21 |
20/04/21 |
ASX - By Stock
|
14
|
5.5K
|
4
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Placement
|
|
Sawvic
|
21 |
6.2K |
1 |
15/04/21 |
15/04/21 |
ASX - By Stock
|
21
|
6.2K
|
1
|
|
ASX - By Stock
|
PTX |
Re:
Cancer-free after 12 years: Why you’re hearing the C-word more often
|
|
Sawvic
|
68 |
34K |
1 |
12/04/21 |
12/04/21 |
ASX - By Stock
|
68
|
34K
|
1
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Investor Presentation
|
|
Sawvic
|
7 |
3.0K |
6 |
08/04/21 |
08/04/21 |
ASX - By Stock
|
7
|
3.0K
|
6
|
|
ASX - By Stock
|
PTX |
Re:
peter Mac
|
|
Sawvic
|
32 |
11K |
2 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
32
|
11K
|
2
|
|
ASX - By Stock
|
PTX |
Re:
peter Mac
|
|
Sawvic
|
32 |
11K |
0 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
32
|
11K
|
0
|
|
ASX - By Stock
|
MDR |
Re:
Ann: MDR Quarterly Report & Appendix 4C
|
|
Sawvic
|
31 |
11K |
0 |
10/02/21 |
10/02/21 |
ASX - By Stock
|
31
|
11K
|
0
|
|
ASX - By Stock
|
TRI |
Re:
Ann: Trading Halt
|
|
Sawvic
|
34 |
11K |
1 |
05/02/21 |
05/02/21 |
ASX - By Stock
|
34
|
11K
|
1
|
|
ASX - By Stock
|
PTX |
Re:
PTX100, Professor H.Miles Prince, Car-T and OmniCAR
|
|
Sawvic
|
145 |
66K |
2 |
01/02/21 |
01/02/21 |
ASX - By Stock
|
145
|
66K
|
2
|
|
ASX - By Stock
|
MDR |
Re:
Ann: MDR Quarterly Report & Appendix 4C
|
|
Sawvic
|
31 |
11K |
2 |
21/01/21 |
21/01/21 |
ASX - By Stock
|
31
|
11K
|
2
|
|
ASX - By Stock
|
MDR |
Re:
Ann: MDR Quarterly Report & Appendix 4C
|
|
Sawvic
|
31 |
11K |
1 |
21/01/21 |
21/01/21 |
ASX - By Stock
|
31
|
11K
|
1
|
|
ASX - By Stock
|
MDR |
Re:
Ann: MDR AGM Presentation
|
|
Sawvic
|
22 |
6.5K |
2 |
15/01/21 |
15/01/21 |
ASX - By Stock
|
22
|
6.5K
|
2
|
|
ASX - By Stock
|
MDR |
Re:
Ann: MDR AGM Presentation
|
|
Sawvic
|
22 |
6.5K |
0 |
12/01/21 |
12/01/21 |
ASX - By Stock
|
22
|
6.5K
|
0
|
|
ASX - By Stock
|
TRI |
Re:
Ann: US FDA advises further data needed for MEBsleep approval
|
|
Sawvic
|
43 |
14K |
5 |
30/12/20 |
30/12/20 |
ASX - By Stock
|
43
|
14K
|
5
|
|
ASX - By Stock
|
MDR |
Re:
Could MDR be a multi-bagger in the next 12 months?
|
|
Sawvic
|
8 |
3.9K |
2 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
8
|
3.9K
|
2
|
|
ASX - By Stock
|
PTX |
Re:
CAR - T Treatment Therapy
|
|
Sawvic
|
117 |
43K |
4 |
13/12/20 |
13/12/20 |
ASX - By Stock
|
117
|
43K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
CAR - T Treatment Therapy
|
|
Sawvic
|
117 |
43K |
6 |
12/12/20 |
12/12/20 |
ASX - By Stock
|
117
|
43K
|
6
|
|
ASX - By Stock
|
IMM |
Re:
Price tomorrow
|
|
Sawvic
|
42 |
21K |
0 |
11/12/20 |
11/12/20 |
ASX - By Stock
|
42
|
21K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Trading Halt
|
|
Sawvic
|
40 |
19K |
7 |
17/11/20 |
17/11/20 |
ASX - By Stock
|
40
|
19K
|
7
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep granted European patent for IMP761
|
|
Sawvic
|
19 |
10K |
4 |
21/10/20 |
21/10/20 |
ASX - By Stock
|
19
|
10K
|
4
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep to present AIPAC Overall Survival data at SABCS 2020
|
|
Sawvic
|
13 |
6.5K |
7 |
19/10/20 |
19/10/20 |
ASX - By Stock
|
13
|
6.5K
|
7
|
|
ASX - By Stock
|
IMM |
Re:
LAG525 Solid and Hematologic Malignancies trial completed
|
|
Sawvic
|
38 |
17K |
1 |
10/10/20 |
10/10/20 |
ASX - By Stock
|
38
|
17K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
LAG525 Solid and Hematologic Malignancies trial completed
|
|
Sawvic
|
38 |
17K |
2 |
10/10/20 |
10/10/20 |
ASX - By Stock
|
38
|
17K
|
2
|
|
ASX - By Stock
|
PTX |
Re:
daily chart update
|
|
Sawvic
|
235 |
85K |
2 |
09/09/20 |
09/09/20 |
ASX - By Stock
|
235
|
85K
|
2
|
|
ASX - By Stock
|
PTX |
Re:
daily chart update
|
|
Sawvic
|
235 |
85K |
2 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
235
|
85K
|
2
|
|
ASX - By Stock
|
MXR |
Re:
Ann: Trading Halt
|
|
Sawvic
|
58 |
19K |
6 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
58
|
19K
|
6
|
|
ASX - By Stock
|
IMM |
Re:
ESMO abstract release
|
|
Sawvic
|
114 |
47K |
4 |
06/09/20 |
06/09/20 |
ASX - By Stock
|
114
|
47K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
Fair Valuation of PTX
|
|
Sawvic
|
266 |
84K |
0 |
18/08/20 |
18/08/20 |
ASX - By Stock
|
266
|
84K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Recruitment of stage 1 of part B in TACTI-002 study complete
|
|
Sawvic
|
23 |
7.6K |
0 |
18/08/20 |
18/08/20 |
ASX - By Stock
|
23
|
7.6K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Investors Are Listening As Immutep Eyes Revolutionary Cancer Treatments
|
|
Sawvic
|
17 |
7.2K |
1 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
17
|
7.2K
|
1
|
|